Somatic mutations of the HER2 kinase domain in lung adenocarcinomas - PubMed (original) (raw)
Multicenter Study
. 2005 Mar 1;65(5):1642-6.
doi: 10.1158/0008-5472.CAN-04-4235.
Takao Takahashi, Masaharu Nomura, Kuntal Majmudar, Makoto Suzuki, Huei Lee, Ignacio I Wistuba, Kwun M Fong, Shinichi Toyooka, Nobuyoshi Shimizu, Takehiko Fujisawa, John D Minna, Adi F Gazdar
Affiliations
- PMID: 15753357
- DOI: 10.1158/0008-5472.CAN-04-4235
Multicenter Study
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas
Hisayuki Shigematsu et al. Cancer Res. 2005.
Abstract
Mutations in the epidermal growth factor receptor gene (EGFR) in lung cancers predict for sensitivity to EGFR kinase inhibitors. HER2 (also known as NEU, EGFR2, or ERBB2) is a member of the EGFR family of receptor tyrosine kinases and plays important roles in the pathogenesis of certain human cancers, and mutations have recently been reported in lung cancers. We sequenced the tyrosine kinase domain of HER2 in 671 primary non-small cell lung cancers (NSCLC), 80 NSCLC cell lines, and 55 SCLCs and other neuroendocrine lung tumors as well as 85 other epithelial cancers (breast, bladder, prostate, and colorectal cancers) and compared the mutational status with clinicopathologic features and the presence of EGFR or KRAS mutations. HER2 mutations were present in 1.6% (11 of 671) of NSCLC and were absent in other types of cancers. Only one adenocarcinoma cell line (NCI-H1781) had a mutation. All HER2 mutations were in-frame insertions in exon 20 and target the identical corresponding region as did EGFR insertions. HER2 mutations were significantly more frequent in never smokers (3.2%, 8 of 248; P=0.02) and adenocarcinoma histology (2.8%, 11 of 394; P=0.003). In 394 adenocarcinoma cases, HER2 mutations preferentially targeted Oriental ethnicity (3.9%) compared with other ethnicities (0.7%), female gender (3.6%) compared with male gender (1.9%) and never smokers (4.1%) compared with smokers (1.4%). Mutations in EGFR, HER2, and KRAS genes were never present together in individual tumors and cell lines. The remarkable similarities of mutations in EGFR and HER2 genes involving tumor type and subtype, mutation type, gene location, and specific patient subpopulations targeted are unprecedented and suggest similar etiologic factors. EGFR, HER2, and KRAS mutations are mutually exclusive, suggesting different pathways to lung cancer in smokers and never smokers.
Similar articles
- EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, Park TI, Han SB, Jheon S, Jung TH, Park JY. Bae NC, et al. Cancer Genet Cytogenet. 2007 Mar;173(2):107-13. doi: 10.1016/j.cancergencyto.2006.10.007. Cancer Genet Cytogenet. 2007. PMID: 17321325 - Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Kosaka T, et al. Cancer Res. 2004 Dec 15;64(24):8919-23. doi: 10.1158/0008-5472.CAN-04-2818. Cancer Res. 2004. PMID: 15604253 - Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
Mounawar M, Mukeria A, Le Calvez F, Hung RJ, Renard H, Cortot A, Bollart C, Zaridze D, Brennan P, Boffetta P, Brambilla E, Hainaut P. Mounawar M, et al. Cancer Res. 2007 Jun 15;67(12):5667-72. doi: 10.1158/0008-5472.CAN-06-4229. Cancer Res. 2007. PMID: 17575133 - Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.
Suda K, Tomizawa K, Mitsudomi T. Suda K, et al. Cancer Metastasis Rev. 2010 Mar;29(1):49-60. doi: 10.1007/s10555-010-9209-4. Cancer Metastasis Rev. 2010. PMID: 20108024 Review. - Epidermal growth factor receptor mutations in lung cancers.
Yatabe Y, Mitsudomi T. Yatabe Y, et al. Pathol Int. 2007 May;57(5):233-44. doi: 10.1111/j.1440-1827.2007.02098.x. Pathol Int. 2007. PMID: 17493170 Review.
Cited by
- Prevalence and treatment of human epidermal growth factor receptor 2-altered non-small cell lung cancer: a retrospective analysis and systematic literature review.
Yap NY, Perumal K, Rajadurai P. Yap NY, et al. Ecancermedicalscience. 2024 Aug 1;18:1734. doi: 10.3332/ecancer.2024.1734. eCollection 2024. Ecancermedicalscience. 2024. PMID: 39421181 Free PMC article. - Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients.
Hong L, Patel S, Drusbosky LM, Xiong Y, Chen R, Geng R, Heeke S, Nilsson M, Wu J, Heymach JV, Wang Y, Zhang J, Le X. Hong L, et al. NPJ Precis Oncol. 2024 Oct 1;8(1):217. doi: 10.1038/s41698-024-00720-9. NPJ Precis Oncol. 2024. PMID: 39354054 Free PMC article. - HER2-targeted therapies beyond breast cancer - an update.
Yoon J, Oh DY. Yoon J, et al. Nat Rev Clin Oncol. 2024 Sep;21(9):675-700. doi: 10.1038/s41571-024-00924-9. Epub 2024 Jul 22. Nat Rev Clin Oncol. 2024. PMID: 39039196 Review. - Pyrotinib in HER2 heterogeneously mutated or amplified advanced non-small cell lung cancer patients: a retrospective real-world study (PEARL).
Yang G, Hao X, Hu J, Dong K, Xu H, Yang L, Zhang S, Yang Y, Xu F, Li J, Wang Y. Yang G, et al. J Natl Cancer Cent. 2021 Aug 13;1(4):139-146. doi: 10.1016/j.jncc.2021.08.001. eCollection 2021 Dec. J Natl Cancer Cent. 2021. PMID: 39036804 Free PMC article. - Targeting HER2 genomic alterations in non-small cell lung cancer.
Zeng J, Ma W, Young RB, Li T. Zeng J, et al. J Natl Cancer Cent. 2021 May 3;1(2):58-73. doi: 10.1016/j.jncc.2021.04.001. eCollection 2021 Jun. J Natl Cancer Cent. 2021. PMID: 39035769 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous